H. Pui

Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based Study

B. Leung, Lifang Li, Jiandong Zhou, 2023, medRxiv.

Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: a population-based cohort study.

Sharen Lee, E. Dee, Jiandong Zhou, 2024, Diabetes & metabolism.